<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679261</url>
  </required_header>
  <id_info>
    <org_study_id>BICATOR</org_study_id>
    <nct_id>NCT02679261</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve</brief_title>
  <acronym>BICATOR</acronym>
  <official_title>Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bicuspid Aortic Valve (BAV) is the most common congenital heart disease affecting 1-2% of the
      population. The aortic dilation and aortic valve degeneration are common complications in
      patients with BAV. Statins have shown a reduction in the expression of metalloproteinases of
      the extracellular matrix observed in aortic aneurisms. Several retrospective studies have
      suggested the benefit of the statins to reduce aortic dilation in patients with BAV.
      Moreover, although statins did not show to be useful in the progression of aortic stenosis,
      different studies have suggested a higher profit when the valve affection is not severe. The
      objective of this study is to determine whether atorvastatin is effective at reducing the
      progression of aortic dilation in patients with BAV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BICATOR is a multicentre (8 centres), randomised, double-blind and placebo-controlled
      clinical trial aimed at evaluating the effect of atorvastatin in reducing progression of
      aortic dilation in patients with BAV. The primary outcome is to determine whether
      atorvastatin is effective in reducing aortic dilation in BAV and secondary outcome is to
      define if atorvastatin treatment slows the progression of aortic valve degeneration (valve
      calcification) in a 3 year follow-up period. 220 patients will be included (110 atorvastatin
      - 110 placebo).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the diameter of ascending aorta by CT (Computed Tomography).</measure>
    <time_frame>3 years</time_frame>
    <description>Determination of the progression of ascending aortic dilation assessed by measuring the change of the diameter of ascending aorta by CT (Computed Tomography).The change of the aortic diameter will be defined by the major difference between the measurements taken in the aortic root and ascending aorta in the initial and final study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the final maximum diameter of the aortic root and the basal measured by CT.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference between the final maximum diameter of the aortic root and the basal measured by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the final maximum diameter of the tubular ascending aorta and the basal measured by CT.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference between the final maximum diameter of the tubular ascending aorta and the basal measured by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the final area of the aortic root and the basal measured by CT.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference between the final area of the aortic root and the basal measured by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the the final area of ascending aorta and the basal measured by CT.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference between the final area of ascending aorta and the basal measured by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the valve Agatston final score and the basal assessed by CT.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference between the valve Agatston final score and the basal assessed by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the final planimetry area of the aortic valve and the basal measured by CT.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference between the final planimetry area of the aortic valve and the basal measured by CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the transvalvular pressure gradient of the aortic valve</measure>
    <time_frame>3 years</time_frame>
    <description>Difference of transvalvular pressure gradient of the aortic valve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of aortic regurgitation jet width basal and final.</measure>
    <time_frame>3 years</time_frame>
    <description>Difference of aortic regurgitation jet width basal and final.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the maximum aortic velocity</measure>
    <time_frame>3 years</time_frame>
    <description>Change of the maximum aortic velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of aortic valve area</measure>
    <time_frame>3 years</time_frame>
    <description>Change of aortic valve area by continuity equation basal and final</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocurrence of Serious Adverse Clinical Events leading to hospitalization and death</measure>
    <time_frame>3 years</time_frame>
    <description>Serious Adverse Clinical Events: Aortic dissection, aortic rupture or need for aortic surgery, cardiovascular death, death of any cause. Combined endpoint of death, aortic dissection or need for aortic or valve surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Bicuspid Aortic Valve</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration Atorvastatin 20 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Oral administration atorvastatin 20 mg per day</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years old with BAV confirmed by transthoracic echocardiography (in case
             of doubts other techniques will be required: transesophageal echocardiography or CT to
             confirm diagnosis).

          -  Valve dysfunction only moderate: in case of aortic stenosis with average gradient &lt; 30
             mmHg and in case of aortic regurgitation a vena contracta &lt; 7 mm or a jet with &lt; 10
             mm.

          -  Aortic valve not show severe calcification by transthoracic echocardiography.

          -  Ascending aortic diameter (Valsalva sinus or tubular ascending aorta) ≤ 50 mm.

          -  The patient must give the consent form signed.

        Exclusion Criteria:

          -  Patients younger than 18.

          -  Patients with uncontrolled hypertension and a history or risk of diabetes mellitus.

          -  Patients who receive statins treatment or other lipid lowering drug or if they have
             indication to be treated according to the current clinical practice guidelines.

          -  Previous cardiac surgery or any surgery of other segments of the aorta.

          -  Previous aortic dissection and/or aortic coarctation.

          -  NYHA functional class III or IV.

          -  Presence or antecedent of liver failure (transaminase &gt; 2 fold the superior limit of
             normal levels according to local laboratory), renal failure (creatinine clearance &lt;
             30ml/min or creatinine &gt; 2.5mg/dl), myopathy or creatine kinase levels &gt; 5 fold the
             superior limit of normality, or other gastrointestinal, hematologic or endocrine
             diseases or any other situation that according to the investigator criteria could
             affect the study treatment evaluation.

          -  Hypersensitivity, intolerance or contraindication to any component of the study drug
             or to the contrast used in CT.

          -  Pregnancy, breastfeeding or desire for pregnancy during the study period. A negative
             pregnancy test (negative gonadotropin) will be required in all fertile women to
             participate in the study.

          -  Participation in another drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Evangelista-Masip, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001 Feb 20;103(7):926-33.</citation>
    <PMID>11181465</PMID>
  </reference>
  <reference>
    <citation>Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrün M, Bax JJ, Koning J, van Urk H, Poldermans D. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006 Jul;32(1):21-6. Epub 2006 Mar 6.</citation>
    <PMID>16520071</PMID>
  </reference>
  <reference>
    <citation>Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006 Jan 15;97(2):279-80. Epub 2005 Nov 21.</citation>
    <PMID>16442379</PMID>
  </reference>
  <reference>
    <citation>McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H, Black A, Kearney S, Kay E, Hill AD, Dietz HC, Redmond JM. Pravastatin reduces Marfan aortic dilation. Circulation. 2011 Sep 13;124(11 Suppl):S168-73. doi: 10.1161/CIRCULATIONAHA.110.012187.</citation>
    <PMID>21911808</PMID>
  </reference>
  <reference>
    <citation>Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M, Rizzo J, Memet R, Feldman M, Dziura J, Brandt CA, Elefteriades JA. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol. 2012 Apr 1;109(7):1050-4. doi: 10.1016/j.amjcard.2011.11.038. Epub 2012 Jan 3.</citation>
    <PMID>22221941</PMID>
  </reference>
  <reference>
    <citation>Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol. 2013 Oct 15;112(8):1240-5. doi: 10.1016/j.amjcard.2013.05.081.</citation>
    <PMID>24079445</PMID>
  </reference>
  <reference>
    <citation>Goel SS, Tuzcu EM, Agarwal S, Aksoy O, Krishnaswamy A, Griffin BP, Svensson LG, Kapadia SR. Comparison of ascending aortic size in patients with severe bicuspid aortic valve stenosis treated with versus without a statin drug. Am J Cardiol. 2011 Nov 15;108(10):1458-62. doi: 10.1016/j.amjcard.2011.06.071.</citation>
    <PMID>22040719</PMID>
  </reference>
  <reference>
    <citation>Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005 Jun 9;352(23):2389-97.</citation>
    <PMID>15944423</PMID>
  </reference>
  <reference>
    <citation>Dichtl W, Alber HF, Feuchtner GM, Hintringer F, Reinthaler M, Bartel T, Süssenbacher A, Grander W, Ulmer H, Pachinger O, Müller S. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol. 2008 Sep 15;102(6):743-8. doi: 10.1016/j.amjcard.2008.04.060. Epub 2008 Jul 2.</citation>
    <PMID>18774000</PMID>
  </reference>
  <reference>
    <citation>Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007 Feb 6;49(5):554-61. Epub 2007 Jan 22.</citation>
    <PMID>17276178</PMID>
  </reference>
  <reference>
    <citation>Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010 Jan 19;121(2):306-14. doi: 10.1161/CIRCULATIONAHA.109.900027. Epub 2010 Jan 4.</citation>
    <PMID>20048204</PMID>
  </reference>
  <reference>
    <citation>Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008 Sep 25;359(13):1343-56. doi: 10.1056/NEJMoa0804602. Epub 2008 Sep 2.</citation>
    <PMID>18765433</PMID>
  </reference>
  <reference>
    <citation>Antonini-Canterin F, Hîrşu M, Popescu BA, Leiballi E, Piazza R, Pavan D, Ginghină C, Nicolosi GL. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol. 2008 Sep 15;102(6):738-42. doi: 10.1016/j.amjcard.2008.04.056. Epub 2008 Jun 26.</citation>
    <PMID>18773999</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic dilation</keyword>
  <keyword>Statins</keyword>
  <keyword>Aortic degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

